Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 5/20 | 0.39 |
| ▸ | METAP1 | P53582 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9800611 | 1.00 | REN (0.43) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL9437467 | 1.00 | REN (0.43) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL7436156 | 1.00 | REN (0.43) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL9676548 | 0.96 | REN (0.43) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL8915949 | 0.94 | REN (0.42) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL25348565 | 0.88 | METAP2 (0.41) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL29100503 | 0.88 | METAP2 (0.41) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL25348570 | 0.88 | METAP2 (0.41) | RENMETAP2METAP1TP53KDM4E | |
| Hydrochloric Acid SCHEMBL9848324 | 0.84 | REN (0.47) | RENMETAP2METAP1TP53KDM4E | |
| SCHEMBL8908821 | 0.83 | SHBG (0.35) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5536816-A | Process for producing amides using catalytic amounts of an N-hydroxy compound | HOFFMANN-LA ROCHE INC. (US) | 1996-07-16 | — | — | US | claimed |
| US-5310740-A | Congestive heart failure, hypotensive agents, antiglaucoma agents; side effect reduction | ABBOTT LABORATORIES (US) | 1994-05-10 | — | — | US | claimed |
| US-5284849-A | Treating hypertension and congestive heart failure | ABBOTT LABORATORIES (US) | 1994-02-08 | — | — | US | claimed |
| EP-0456185-A2 | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-11-13 | — | — | EP | claimed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| EP-0509354-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-08-23 | — | — | EP | disclosed |
| EP-0611774-B1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | HOFFMANN LA ROCHE (CH) | 1999-05-26 | — | — | EP | disclosed |
| US-5750649-A | REACTING ACID AND AMINE IN PRESENCE OF CARBODIIMIDE DEHYDRATING AGENT AND N-HYDROXY COMPOUND; PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5688946-A | DIPEPTIDES FOR HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | HOFFMANN LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5536816-A | Process for producing amides using catalytic amounts of an N-hydroxy compound | HOFFMANN-LA ROCHE INC. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5393875-A | Hypotensive, cardiotonic and antiischemic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5278161-A | Racemic mixtures | HOFFMANN-LA ROCHE INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0572909-A1 | Amino acid derivatives as renin inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-08 | — | — | EP | disclosed |
| EP-0543245-A1 | Renin inhibiting amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-26 | — | — | EP | disclosed |
| EP-0509354-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-21 | — | — | EP | disclosed |
| EP-0499080-A2 | Aminoacid derivatibes | MERCK PATENT GmbH (DE) | 1992-08-19 | — | — | EP | disclosed |
| EP-0464572-A2 | Aminoacid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456185-A2 | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-11-13 | — | — | EP | disclosed |
| EP-0416373-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | REN 1827/4885METAP2 2044/4885METAP1 1920/4885 |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | REN 1827/4885METAP2 2044/4885METAP1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.